Contribution of epithelial plasticity to therapy resistance
Entity
UAM. Departamento de Bioquímica; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM)Publisher
MDPI, Basel, SwitzerlandDate
2019-05-14Citation
10.3390/jcm8050676
Journal of Clinical Medicine 8 (2019): 676
ISSN
2077-0383DOI
10.3390/jcm8050676Funded by
This work was supported by grants from the Spanish Ministerio de Economía y Competividad (SAF2013-44739-R, SAF2016-76504-R) and Instituto de Salud Carlos III (CIBERONC 16/12/00295; PI16/00134), all of them partly supported by EU-FEDER fund, FC AECC (Grupos Estables de Investigación 2018-AECC) and Worldwide Cancer Research UK (formerly AICR, 12-1057 and 16-0295)Project
Gobierno de España. SAF2013-44739-R; Gobierno de España. SAF2016-76504-R; Gobierno de España. CIBERONC 16/12/00295; Gobierno de España. PI16/00134Editor's Version
https://doi.org/10.3390/jcm8050676Subjects
Epithelial–mesenchymal transition; Hybrid E/M states; Plasticity; Tumour heterogeneity; Treatment resistance; Immunotherapy scape; MedicinaRights
© 2019 by the authorsAbstract
Therapy resistance is responsible for tumour recurrence and represents one of the major
challenges in present oncology. Significant advances have been made in the understanding of the
mechanisms underlying resistance to conventional and targeted therapies improving the clinical
management of relapsed patients. Unfortunately, in too many cases, resistance reappears leading to a
fatal outcome. The recent introduction of immunotherapy regimes has provided an unprecedented
success in the treatment of specific cancer types; however, a good percentage of patients do not
respond to immune-based treatments or ultimately become resistant. Cellular plasticity, cancer cell
stemness and tumour heterogeneity have emerged as important determinants of treatment resistance.
Epithelial-to-mesenchymal transition (EMT) is associated with resistance in many di erent cellular
and preclinical models, although little evidence derives directly from clinical samples. The recognition
of the presence in tumours of intermediate hybrid epithelial/mesenchymal states as the most likely
manifestation of epithelial plasticity and their potential link to stemness and tumour heterogeneity,
provide new clues to understanding resistance and could be exploited in the search for anti-resistance
strategies. Here, recent evidence linking EMT/epithelial plasticity to resistance against conventional,
targeted and immune therapy are summarized. In addition, future perspectives for related clinical approaches are also discussed
Files in this item
Google Scholar:Santamaría, Patricia G.
-
Moreno Bueno, Gema
-
Cano, Amparo
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Prostaglandin F 2α-induced prostate transmembrane protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity
Jiménez-Segovia, Alba; Mota, Alba; Rojo-Sebastián, Alejandro; Barrocal, Beatriz; Rynne-Vidal, Ángela; García-Bermejo, Mara-Laura; Gómez-Bris, Raquel; Hawinkels, Lukas J.A.C.; Sandoval, Pilar; García-Escudero, Ramón; López-Cabrera, Manuel; Moreno Bueno, Gema; Fresno Escudero, Manuel; Stamatakis Andriani, Konstantinos; Centro de Biología Molecular Severo Ochoa (CBMSO); Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)
2019 -
Corrigendum to “Prostaglandin F2a-induced prostate transmembrane protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity” [Neoplasia 21 (2019) 1073–1084]
Jiménez-Segovia, Alba; Mota, Alba; Rojo-Sebastián, Alejandro; Barrocal, Beatriz; Rynne-Vidal, Ángela; García-Bermejo, María Laura; Gómez-Bris, Raquel; Hawinkels, Lukas J A C; Sandoval, Pilar; García-Escudero, Ramón; López-Cabrera, Manuel; Moreno Bueno, Gema; Fresno Escudero, Manuel; Stamatakis Andriani, Konstantinos
2020-05